[23] Something interesting to note about this study is the lack of dose response in the findings
Cai CX, Nishimura A, Baxter S, et al
Wegovy Just like with semaglutide, tirzepatide has two brand names: Mounjaro: FDA-approved for Type 2 Diabetes Maximum dose: 15 mg weekly Prescribed primarily for blood sugar control Zepbound: FDA-approved for weight management Same maximum dose: 15 mg weekly Marketed for obesity treatment The drugs are chemically identical, but the legal considerations mirror the Ozempic/Wegovy distinction: Different labels and warnings Different approved uses Potential off-label prescribing Different marketing claims Case Example: Tirzepatide Injury Patient Profile: 52-year-old woman with BMI 34 No diabetes, seeking weight loss Prescribed Zepbound, escalated to 15 mg Timeline: Month 1-3: Excellent weight loss (25 lbs), manageable nausea Month 4: Persistent vomiting began Month 5: Unable to eat solid food, lost 15 more lbs Month 6: Diagnosed with severe gastroparesis via gastric emptying scan Current: 12 months post-discontinuation, still cannot eat normally, requires liquid diet Legal Claim: Inadequate warnings about permanence of gastroparesis Marketing emphasized dramatic weight loss without proper risk disclosure Failure to inform that condition might not resolve after stopping Damages include ongoing medical care, lost wages, diminished quality of life 5
Calling both "GLP-1 support" is technically accurate but practically misleading
A simplified GLP-1 manufacturing process typically includes the following stages: The peptide chain is assembled sequentially on a solid resin through repeated cycles of: Following synthesis, the peptide is cleaved from the resin and precipitated to isolate crude material
Are peptides and Ozempic the same thing
